Bortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces
podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney.
Literature has reported that bortezomib can achieve a complete response rate of up to 38% in
the treatment of glomerular diseases, but its safety and effectiveness remain to be assessed
for the Chinese demographic. This study attempts to explore a new treatment plan for
glomerular disease by observing the therapeutic effect of bortezomib on glomerular disease.